ALX Oncology Stock (NASDAQ:ALXO)


ForecastRevenueOwnershipFinancialsChart

Previous Close

$1.45

52W Range

$1.33 - $17.82

50D Avg

$1.86

200D Avg

$8.70

Market Cap

$78.48M

Avg Vol (3M)

$749.87K

Beta

1.00

Div Yield

-

ALXO Company Profile


ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

81

IPO Date

Jul 17, 2020

Website

ALXO Performance


ALXO Financial Summary


Dec 23Dec 22Dec 21
Revenue---
Operating Income$-170.28M$-127.44M$-83.56M
Net Income$-160.81M$-123.48M$-83.46M
EBITDA$-170.28M$-127.44M$-83.47M
Basic EPS-$-3.03$-2.07
Diluted EPS-$-3.03$-2.07

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison


TickerCompany
CGEMCullinan Oncology, Inc.
DYNDyne Therapeutics, Inc.
RVMDRevolution Medicines, Inc. Warrant
EYPTEyePoint Pharmaceuticals, Inc.
BCABBioAtla, Inc.
MLYSMineralys Therapeutics, Inc.
BMEABiomea Fusion, Inc.
EWTXEdgewise Therapeutics, Inc.
STOKStoke Therapeutics, Inc.
IPSCCentury Therapeutics, Inc.
AVTEAerovate Therapeutics, Inc.
IMTXImmatics N.V.
BDTXBlack Diamond Therapeutics, Inc.
BCELAtreca, Inc.
VIRXViracta Therapeutics, Inc.
CABACabaletta Bio, Inc.
PASGPassage Bio, Inc.
CCCCC4 Therapeutics, Inc.
CRNXCrinetics Pharmaceuticals, Inc.